At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 30 enrolled
Drug / intervention
Ibrutinib +2 moredrug
Likely dose
Ibrutinib 560mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of iR2 (Ibrutinib，Lenalidomide, Rituximab）in Untreated and Unfit Elderly Patients With Diffuse Large B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib, Lenalidomide, and 1 other intervention for Diffuse Large B Cell Lymphoma. Targeting 30 participants across 1 site.
Detailed Summary
This is a single-arm, open-label phase 2 study of iR2 in the treatment of unfit and elderly patients with untreated diffuse large B-cell lymphoma。
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B Cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedMay 2019
Primary CompletionMar 2021
Study CompletionMay 2022
TodayJul 2026
First PostedMay 14, 2019
Enrollment StartMar 13, 2019
Primary CompletionMar 1, 2021
Study CompletionMay 1, 2022
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 7.1 years ago
Interventions
Ibrutinibdrug
Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
Lenalidomidedrug
Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
Rituximabdrug
Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles